abusesaffiliationarrow-downarrow-leftarrow-rightarrow-upattack-typeburgerchevron-downchevron-leftchevron-rightchevron-upClock iconclosedeletedevelopment-povertydiscriminationdollardownloademailenvironmentexternal-linkfacebookfiltergenderglobegroupshealthC4067174-3DD9-4B9E-AD64-284FDAAE6338@1xinformation-outlineinformationinstagraminvestment-trade-globalisationissueslabourlanguagesShapeCombined Shapeline, chart, up, arrow, graphLinkedInlocationmap-pinminusnewsorganisationotheroverviewpluspreviewArtboard 185profilerefreshIconnewssearchsecurityPathStock downStock steadyStock uptagticktooltiptwitteruniversalityweb
Article

11 Jun 2004

Author:
Stephen Foley, Independent [UK]

GSK fights back in battle with Spitzer over Seroxat

Glaxosmithkline, the UK drugs giant facing a legal onslaught from the New York state attorney general, yesterday moved to shore up its reputation for probity by promising to publish research on the safety of its leading antidepressant which Eliot Spitzer claims has been illegally kept secret since 1998.